New Data Demonstrate the Health Economic Benefits of Nevro’s High-Frequency Spinal Cord Stimulation Therapy

Publications Show Reductions in Hospital Resource Utilization Associated with 10 kHz Therapy Spinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Nonsurgical Refractory Back Pain REDWOOD CITY, Calif., Sept. 18, 2023 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a…

Click here to view original post